Borderline personality disorder personality problems
Conditions
Interventions
1. Mentalization-Based Treatment (MBT)
2. Schema Therapy (ST)
There are two different intervention conditions, MBT or ST, which participants
are randomly assigned to. Both treatments will consist of
Borderline personality disorder
Sponsors
Universiteit van Amsterdam
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: 1. Primary diagnosis of BPD 2. Age 18-65 years 3. Borderline Personality Disorder Severity Index, fourth edition (BPDSI-IV) score above 20 4. Dutch literacy 5. The willingness and ability to participate in (group) treatment for at least 24 months
Exclusion criteria
Exclusion criteria: 1. Psychotic disorder (except short reactive psychotic episodes, see BPD criterion 9 of the DSM-5) 2. Severe addiction requiring clinical detoxification (after which entering is possible) 3. Bipolar I disorder (except when in full remission) 4. IQ
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measure is change in the severity and frequency of the DSM-5 BPD manifestations (BPDSI-IV, total score; Arntz et al., 2003; Giesen-Bloo, Wachters, Schouten, & Arntz, 2010). This outcome measure is frequently used in other studies of ST: Giesen-Bloo et al. (2006), Van Asselt et al. (2008), Nadort et al. (2009), and Wetzelaer et al. (2014). | — |
Secondary
| Measure | Time frame |
|---|---|
| As accumulating evidence suggests that symptoms and level of functioning are only loosely associated, attention will be paid to outcome in terms of both symptom change and functioning, including relational, occupational, and personal (wellbeing) functioning. Therefore, the secondary outcome measures will include: * DSM-5 diagnostic status, assessed by the Structured Clinical Interviews for the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) Clinician Version (SCID-5-CV) and Personality Disorders (SCID-5-PD)*. * BPDSI-IV (Arntz et al., 2003; Giesen-Bloo et al., 2010) reliable change and recovery (i.e., score below 15). * Dimensional scores for each of the DSM-5 BPD-criteria as assessed with the BPDSI-IV (Arntz et al., 2003; Giesen-Bloo et al., 2006). * Psychopathology, personality characteristics, and behavioral proclivities, assessed by the Minnesota Multiphasic Personality Inventory-2 Restructured Form (MMPI-2-rf; Ben-Porath & Tellegen, 2008). * General functioning, including work/study and societal participation, assessed by the WHO Disability Assessment Schedule (WHODAS 2.0; Üstün, Kostanjsek, Chatterji, & Rehm, 2010). * General psychopathology as measured with the Brief Symptom Inventory (BSI; Derogatis & Melisaratos, 1983). * Quality of life, assessed using the EuroQol EQ-5D-5L (Rabin & Charro, 2001). * Happiness, measured with a single question on general happiness (Veenhoven, 2008). * Sleep, measured using the Insomnia Sleep Index (Bastien, Vallières, & Morin, 2001) and two items measuring nightmare frequency. * Costs, including healthcare, patient and family costs and costs outside the health care sector, will be measured using a retrospective cost interview especially designed for BPD patients (Wetzelaer et al., 2014). Both treatments include non-specific (attachment and alliance) and specific (mentalization in MBT and schema modes in ST) mechanisms of change. Measures of the mechanisms of change will include: | — |
Countries
The Netherlands
Outcome results
None listed